Anti-Cancer Drugs最新文献_第3页

BRD9 promotes the malignant phenotype of thyroid cancer by activating the MAPK/ERK pathway. BRD9通过激活MAPK/ERK通路促进甲状腺癌的恶性表型。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-06-01 Epub Date: 2025-02-04 DOI: 10.1097/CAD.0000000000001694

Yingcheng Deng, Yilin Li, Hong Cao

{"title":"BRD9 promotes the malignant phenotype of thyroid cancer by activating the MAPK/ERK pathway.","authors":"Yingcheng Deng, Yilin Li, Hong Cao","doi":"10.1097/CAD.0000000000001694","DOIUrl":"10.1097/CAD.0000000000001694","url":null,"abstract":"Thyroid cancer is one of the most common endocrine gland malignancies in China. During gene transcription, the bromodomain and extraterminal domain (BET) proteins perform epigenome interpretation tasks. Bromodomain-containing protein 9 (BRD9) is one of the BET family members. Increasing evidence has implicated that BRD9 plays significant roles in multiple malignancies. However, its role in thyroid cancer is still not fully understood. In this research, our results demonstrated that high expression of BRD9 can facilitate the malignant phenotype of thyroid cancer cell lines, while low expression of BRD9 can impede the malignant phenotype of thyroid cancer cell lines. Pharmacologically, I-BRD9 treatment inhibits the proliferation and promotes the rate of apoptosis in thyroid cancer cell lines. Moreover, our results also revealed that BRD9 promoted xenograft tumor growth. In addition, our study showed that the expression of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated protein kinase (ERK) pathway-related proteins was decreased in BRD9 knockdown thyroid cancer cells, such as Raf, ERK, p-ERK, c-Fos, and c-Myc, which could be significantly reversed by overexpressing the BRD9 in different thyroid cancer cells. After the specific inhibitor of ERK (SCH772984) was applied to thyroid cancer cells (BCPAP cells) overexpressing the BRD9 gene, the results suggested that SCH772984 reverses the high expression of MAPK/ERK pathway-associated protein in BCPAP cells (over-expression BRD9 cells). In conclusion, this study demonstrated that BRD9 was highly expressed in serum and malignant tumor tissues of thyroid cancer patients and further promoted the development of the malignant phenotype of thyroid cancer by activating the MAPK/ERK signaling pathway.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"359-373"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11969370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years. 欣替单抗联合口服维诺瑞滨作为一线治疗新诊断的IIIB-IV期非小细胞肺癌患者的临床疗效和安全性，表现状态2或年龄≥75岁。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-06-01 Epub Date: 2025-02-14 DOI: 10.1097/CAD.0000000000001699

Wenzhong Su, Jianqiang Li

{"title":"Clinical efficacy and safety of sintilimab plus oral vinorelbine as first-line treatment for newly diagnosed stage IIIB-IV nonsmall cell lung cancer patients with performance status 2 or age ≥75 years.","authors":"Wenzhong Su, Jianqiang Li","doi":"10.1097/CAD.0000000000001699","DOIUrl":"10.1097/CAD.0000000000001699","url":null,"abstract":"This study aimed to evaluate the efficacy and safety of sintilimab combined with oral vinorelbine in newly diagnosed patients with stage IIIb to IV nonsmall cell lung cancer (NSCLC) who had an Eastern Cooperative Oncology Group performance status (PS) of 2 or over 75 years of age during the initial treatment. This prospective single-center single-arm study enrolled patients with histologically confirmed NSCLC. Eligible patients were administered sintilimab and vinorelbine. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included objective response rate (ORR) and disease control rate (DCR). Furthermore, this study assessed indicators of treatment response and safety. From September 2020 to December 2023, 60 eligible patients were enrolled in the Respiratory Department of Shanxi Cancer Hospital. Following treatment, PFS was 9.1 months, and ORR and DCR were 39.6 and 63.79%, respectively. In addition, there was a reduction in blood tumor marker levels and enhanced immune function. Adverse reactions had a relatively low incidence and primarily consisted of grade 1-2 cases. Sintilimab plus oral vinorelbine showed promising efficacy and safety as a first-line treatment strategy for patients with NSCLC with PS 2 or elderly patients. It also optimizes immune function in patients with NSCLC.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"401-407"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of disitamab vedotin (RC48) for previously treated human epidermal growth factor receptor 2-positive breast cancer with symptomatic brain metastases: a case report and review of the literature. 地西他麦维多汀（RC48）治疗既往治疗的人表皮生长因子受体2阳性乳腺癌伴症状性脑转移的疗效：1例报告及文献回顾

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-06-01 Epub Date: 2025-03-04 DOI: 10.1097/CAD.0000000000001702

Can Yang, Cui Zhang, Yisidan Huang, Xiong Zhu, Jia Jiang, Yuting Zeng, Hanqun Zhang, Libo Li, Yuncong Liu, Yong Li

{"title":"Efficacy of disitamab vedotin (RC48) for previously treated human epidermal growth factor receptor 2-positive breast cancer with symptomatic brain metastases: a case report and review of the literature.","authors":"Can Yang, Cui Zhang, Yisidan Huang, Xiong Zhu, Jia Jiang, Yuting Zeng, Hanqun Zhang, Libo Li, Yuncong Liu, Yong Li","doi":"10.1097/CAD.0000000000001702","DOIUrl":"10.1097/CAD.0000000000001702","url":null,"abstract":"Local radiotherapy or surgery is the standard of care for treating brain metastases among patients with breast cancer. However, affected by tumor subtype, more than 50% of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases will still develop local recurrence or new brain lesions within 1 year after radiotherapy. As systemic therapies demonstrate higher and clinically relevant levels of intracranial activity and longer survival, there is limited evidence to guide how to weigh the options of radiotherapy versus systemic therapy (and deferral of radiation) in patients with progressive brain metastases, particularly those that are symptomatic. This study presents a case of progressive symptomatic HER2-positive brain metastases in a patient previously treated with whole brain radiotherapy and various targeted therapies. Due to limited access to novel HER2-targeted drugs, a new antibody-drug conjugate drug, disitamab vedotin (RC48) monotherapy, was chosen for postprogression treatment. The patient experienced rapid relief of neurological symptoms, partial regression of the brain tumor, and sustained disease remission for over 12 months without any treatment-related toxicity, also avoided reirradiation exposure and potential neurocognitive decline. The treatment of brain metastasis has been a topic of ongoing discussion. Our experience may offer valuable insights into managing HER2-positive progressive symptomatic brain metastases.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"440-445"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anlotinib for the treatment of pulmonary epithelioid inflammatory myofibroblastic sarcoma: a case report. 安洛替尼治疗肺上皮样炎性肌成纤维细胞肉瘤1例。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-05-12 DOI: 10.1097/CAD.0000000000001731

Huanling Zeng, Xin Li, Shengli Chen, Jiajian Xu, Yue Xiao, Yuhua Zhao

引用次数: 0

Complete response with trastuzumab in heavily pretreated HER2-positive metastatic salivary duct carcinoma. 曲妥珠单抗在重度预处理的her2阳性转移性涎管癌中的完全缓解。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-05-06 DOI: 10.1097/CAD.0000000000001733

Rumeysa Çolak, Caner Kapar, Mesut Yilmaz

{"title":"Complete response with trastuzumab in heavily pretreated HER2-positive metastatic salivary duct carcinoma.","authors":"Rumeysa Çolak, Caner Kapar, Mesut Yilmaz","doi":"10.1097/CAD.0000000000001733","DOIUrl":"https://doi.org/10.1097/CAD.0000000000001733","url":null,"abstract":"Salivary duct carcinoma (SDC), an aggressive and relatively rare tumor, accounts for approximately 10% of all salivary gland malignancies. We report a case of a patient with a metastatic, human epidermal growth factor receptor 2 (HER2)-positive parotid SDC efficiently treated with docetaxel and trastuzumab combination after multiple series of chemotherapies. A 61-year-old man presented with SDC. After adjuvant radiotherapy, imaging revealed multiple metastatic lesions in the lungs. Systemic treatment with carboplatin and paclitaxel was initiated. After disease progression, doxorubicin, vinorelbine, and capecitabine were performed. Neurotrophic tropomyosin receptor kinase and AR (androgen receptor) were negative. Immunohistochemistry determined a HER2-positive score of 3. After multiple chemotherapy, the patient was started with combination of docetaxel and trastuzumab. A complete response was obtained after 3 months of treatment in the patient. In conclusion, SDCs are highly aggressive malignant tumors. Targeted therapy with trastuzumab targeting HER2 overexpression is a reasonable option in metastatic settings.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimodal treatment with cisplatin for metastatic disease in malignant peripheral nerve sheath tumors: a case report and review. 顺铂多模式治疗转移性恶性周围神经鞘肿瘤1例报告及回顾。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-05-01 DOI: 10.1097/CAD.0000000000001722

Rossella Hakim, Maria Cristina Salone, Giovanni Bozza, Paolo Spinnato, Alessandra Longhi

引用次数: 0

Palbociclib stimulates CD8+ T cell response in triple-negative breast cancer via regulating phosphoglycerate dehydrogenase. 帕博西尼通过调节磷酸甘油脱氢酶刺激三阴性乳腺癌的CD8+ T细胞反应。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-05-01 DOI: 10.1097/CAD.0000000000001725

Yuanyuan Sun, Yaqing Li, Yunwei Han, Chenying Liu, Yuanming Song, Guangshen Gao

{"title":"Palbociclib stimulates CD8+ T cell response in triple-negative breast cancer via regulating phosphoglycerate dehydrogenase.","authors":"Yuanyuan Sun, Yaqing Li, Yunwei Han, Chenying Liu, Yuanming Song, Guangshen Gao","doi":"10.1097/CAD.0000000000001725","DOIUrl":"https://doi.org/10.1097/CAD.0000000000001725","url":null,"abstract":"CDK4/6 inhibitors are applied for the treatment of breast cancer. The purpose of this study was to explore the effects of palbociclib (PALB) on triple-negative breast cancer. An in vivo assay was applied to determine the effects of PALB on breast cancer. Gene expression was detected using immunohistochemistry. mRNA levels were detected using reverse transcription-quantitative PCR. Protein expression was detected using western blot. The expansion of CD8+ T cell subsets was detected using flow cytometry. We found that PALB treatment promoted the persistence of CD8+ T cells, manifested by the maintenance of stem-like CD8+ T cells and effector T cells. Moreover, PALB downregulated PHGDH, high levels of which predicted poor prognosis of breast cancer patients. Moreover, overexpression of PHGDH antagonized the effects of PALB and suppressed the persistence of CD8+ T cells. Additionally, PALB enhanced the effects of anti-PD1 immunotherapy and suppressed the tumor growth of breast cancer. In summary, PALB promoted the maintenance of CD8+ memory precursors in breast cancer via downregulating PHGDH.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of immune checkpoint inhibitors rechallenge and metronomic cyclophosphamide with or without bevacizumab in metastatic nonsmall cell lung cancer. 免疫检查点抑制剂再挑战和节拍环磷酰胺联合或不联合贝伐单抗治疗转移性非小细胞肺癌的疗效

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-04-30 DOI: 10.1097/CAD.0000000000001723

Aram A Musaelyan, Svetlana V Odintsova, Magaripa A Urtenova, Ekaterina P Solovyova, Liliana V Kindyalova, Sergey V Orlov

{"title":"Efficacy of immune checkpoint inhibitors rechallenge and metronomic cyclophosphamide with or without bevacizumab in metastatic nonsmall cell lung cancer.","authors":"Aram A Musaelyan, Svetlana V Odintsova, Magaripa A Urtenova, Ekaterina P Solovyova, Liliana V Kindyalova, Sergey V Orlov","doi":"10.1097/CAD.0000000000001723","DOIUrl":"https://doi.org/10.1097/CAD.0000000000001723","url":null,"abstract":"Objective: The present study aims to evaluate the efficacy of immune checkpoint inhibitor (ICI) rechallenge in combination with metronomic cyclophosphamide, with or without bevacizumab, in patients with metastatic nonsmall cell lung cancer (NSCLC) and to investigate the clinical characteristics associated with the response to the therapy.Materials and methods: The study included 43 patients with metastatic NSCLC who responded to ICIs for ≥4 months and subsequently experienced disease progression. The patients then underwent ICI rechallenge along with either oral cyclophosphamide daily alone (n = 24) or cyclophosphamide and bevacizumab (n = 19).Results: Combining ICI with cyclophosphamide resulted in an objective response rate (ORR) of 16.7%, disease control rate (DCR) of 75.0%, median progression-free survival (PFS) of 5.8 months, and overall survival (OS) of 15.4 months. Oral cyclophosphamide and bevacizumab cohort achieved an ORR of 26.3%, a DCR of 78.9%, a PFS of 6.8 months, and an OS of 17.6 months. No treatment-related adverse events resulted in the discontinuation of the study therapy in either cohort. Multivariate analysis demonstrated that the absence of an objective response to initial ICIs (OS: P = 0.016), poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) (PFS: P = 0.017, OS: P = 0.032), and a neutrophil-to-lymphocyte ratio (NLR) ≥ 3.8 (PFS: P = 0.004, OS: P = 0.007) were negative predictors of rechallenge therapy.Conclusion: The combination showed promising antitumor activity and a well-tolerated safety profile in patients with ICI-pretreated NSCLC. Furthermore, ECOG PS 0-1, objective response, and NLR ≤ 3.8 were predictive of the efficacy of the study therapy.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma. 转移性黑色素瘤患者的尼武单抗和伊匹单抗诱导的肌炎、重症肌无力和心肌炎。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-04-23 DOI: 10.1097/CAD.0000000000001727

Berin Inan, Ulkuhan Duzgun, Zeynep Ergul-Ulger, Can Ebru Bekircan-Kurt, Busra Nur Ceylan, Omer Karadas, Zeki Odabasi

{"title":"Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma.","authors":"Berin Inan, Ulkuhan Duzgun, Zeynep Ergul-Ulger, Can Ebru Bekircan-Kurt, Busra Nur Ceylan, Omer Karadas, Zeki Odabasi","doi":"10.1097/CAD.0000000000001727","DOIUrl":"https://doi.org/10.1097/CAD.0000000000001727","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have revolutionized advanced cancer treatment and prolonged survival; however, they are associated with several immune-related adverse events in up to 60% of patients, affecting various organ systems. A 73-year-old male patient with metastatic melanoma was admitted with left-sided ptosis, diplopia, head drop, and proximal muscle weakness. The patient had been undergoing treatment with nivolumab and ipilimumab, and his symptoms emerged 4 days after receiving the second cycle of the immunotherapy regimen. He was diagnosed as having ICI-related myositis, myasthenia gravis (MG), and myocarditis based on electromyography, muscle biopsy, antibody status, troponin level, and cardiac evaluation. ICIs were withdrawn and the patient was treated with intravenous methylprednisolone, intravenous immunoglobulin, and plasma exchange; however, the patient was treatment-refractory, necessitating long-term immunosuppression with rituximab. Subsequently, he responded well, and nivolumab monotherapy was resumed. The patient has been neurologically stable for 4 months without any recurrence of ICI-related adverse effects. ICI-related myositis, MG, and myocarditis are rare but can be severe and potentially life-threatening. Therefore, early recognition and immediate treatment are crucial for improving prognosis. To the best of our knowledge, this is the only case with nivolumab- and ipilimumab-induced triple overlap syndrome successfully treated with rituximab.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deubiquitinating enzyme UCHL1 stabilizes CAV1 to inhibit ferroptosis and enhance docetaxel resistance in nasopharyngeal carcinoma. 去泛素化酶UCHL1稳定CAV1抑制铁下垂，增强鼻咽癌多西他赛耐药。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2025-04-23 DOI: 10.1097/CAD.0000000000001721

Yixian Ye, Peng Wang, Daquan Wu, Fengrong Tang, Na Shen, Guanghui Hou

{"title":"Deubiquitinating enzyme UCHL1 stabilizes CAV1 to inhibit ferroptosis and enhance docetaxel resistance in nasopharyngeal carcinoma.","authors":"Yixian Ye, Peng Wang, Daquan Wu, Fengrong Tang, Na Shen, Guanghui Hou","doi":"10.1097/CAD.0000000000001721","DOIUrl":"https://doi.org/10.1097/CAD.0000000000001721","url":null,"abstract":"The overexpression of CAV1 in many cancers is linked to chemotherapy resistance, but the exact mechanisms by which CAV1 contributes to resistance in nasopharyngeal carcinoma (NPC) are not fully known. Our research aims to elucidate the potential pathways by which CAV1 contributes to chemotherapy resistance in NPC, providing a basis for developing strategies to overcome resistance. A docetaxel-resistant NPC cell line was established, and CAV1 expression was analyzed in the cell line and the resistant variant using western blot. The sensitivity of the resistant cell line to docetaxel was assessed via cell counting kit-8, colony formation assays, and flow cytometry. Flow cytometry was used to measure lipid reactive oxygen species levels, while kits were employed to determine Fe2+ and malondialdehyde concentrations. The Ubibrowser database helped identify ubiquitination enzymes that interact with CAV1. The binding relationship between UCHL1 and CAV1 was studied using co-immunoprecipitation and immunofluorescence, which also evaluated the deubiquitination activity of UCHL1 on CAV1. CAV1 is overexpressed in NPC tissues and cells, correlating with adverse patient prognoses. In docetaxel-resistant cells, CAV1 expression is elevated compared to standard NPC cells. Silencing CAV1 increased the sensitivity of these resistant cells to docetaxel. Additionally, treatment with the ferroptosis inducer erastin could counteract the effects of CAV1 overexpression on drug resistance. UCHL1 interacted with CAV1 and inhibited its ubiquitin-mediated degradation pathway. By deubiquitinating CAV1, UCHL1 stabilizes and increases its expression, which inhibits ferroptosis and enhances the resistance of NPC cells to docetaxel.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0